I like this post. We are slowly transitioning to a period where PER could potentially become a more interesting prospect to Pharma companies. For exactly the reasons RYNZN points out.
The double blinded placebo controlled trial, and tox study, all supported with targeted Biomarkers are all risk reducing. We just need to replicate the results from the last trial.
The market cap is very low for where PER is in this process. But the market still hates risk. These future announcements will address this.
As Sam says, we wait.
- Forums
- ASX - By Stock
- When US tox study due
I like this post. We are slowly transitioning to a period where...
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.3¢ |
Change
-0.002(2.35%) |
Mkt cap ! $74.82M |
Open | High | Low | Value | Volume |
8.3¢ | 8.4¢ | 8.3¢ | $33.95K | 407.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 12164 | 8.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 1366 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 12164 | 0.082 |
2 | 143500 | 0.081 |
2 | 106250 | 0.080 |
3 | 132078 | 0.079 |
2 | 120924 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 1366 | 1 |
0.085 | 136669 | 3 |
0.086 | 27375 | 1 |
0.087 | 429525 | 2 |
0.088 | 457142 | 2 |
Last trade - 15.57pm 03/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |